Device Trial Radar · NCT07725419
Transcutaneous Pulsed Radiofrequency for the Treatment of Diabetic Peripheral Neuropathy Pain
Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
Dec 2016
Primary completion
Aug 2019
Study completion Aug 2019
Sponsor
- Lead sponsor
- Algiamed Technologies USA, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Xavant Technology (Pty) Ltd
- First posted
- Jul 24, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if a non-invasive, electrical pulsed radio frequency (PRF) device can relieve pain and improve function in patients suffering from diabetic nerve pain in their feet, known as pedal diabetic peripheral neuropathy. Patients with this condition often experience severe pain, burning sensations, numbness, and tingling. Current medications for diabetic nerve pain often have unwanted side effects or do not provide sufficient relief. In this single-blind, randomized trial, participants are assigned to receive either an active PRF treatment or a placebo (sham) treatment. Both treatments involve placing the device safely behind the knee (targeting the sciatic nerve) for 10 minutes, once a week for 3 weeks. The main question this study aims to answer is whether the active PRF treatment reduces nerve pain and symptoms significantly more than the placebo, measured by standard symptom questionnaires over a 6-month period.
Conditions
- Diabetic Peripheral Neuropathic Pain (DPN)
- Diabetic Peripheral Neuropathy
- Diabetic Peripheral Neuropathic Pain
Interventions
NMS 460 Pulsed Radio Frequency DeviceDevice
Active transcutaneous electrical pulsed radio frequency stimulation. The device is applied bilaterally at the sciatic nerve in the popliteal fossa for 10 minutes, once weekly for 3 consecutive weeks.
Placebo DeviceDevice
A sham device designed to look and operate like the active device but delivering no therapeutic current. It is applied bilaterally at the sciatic nerve in the popliteal fossa for 10 minutes, once weekly for 3 consecutive weeks to mimic the active treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Neuropathic Pain and Symptoms as Measured by the DN4 TestTime frame: Baseline, prior to the third treatment (Week 3), and at 1, 3, and 6 months after the last treatment.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Centre for Diabetes and Endocrinology (CDE), Houghton
Johannesburg, Gauteng, South Africa
Clinical Sites - West Johannesburg
Johannesburg, Gauteng, South Africa
Diabetic Clinic at the Charlotte Maxeke Hospital
Johannesburg, Gauteng, South Africa
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.